মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
Vixo is indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of at Least 1 m2: The recommended dosage of Larotrectinib is 100 mg orally twice daily, with or without food, until disease progression or until unacceptable toxicity. Recommended Dosage in Pediatric Patients with Body Surface Area Less Than 1 m2: The recommended dosage of Larotrectinib is 100 mg/m2 orally twice daily, with or without food, until disease progression or until unacceptable toxicity. Whole capsules should be swallowed with water and the capsules should not be chewed or crushed. A missed dose should not be made up within 6 hours of the next scheduled dose. If vomiting occurs after taking a dose of Larotrectinib, the next dose should be taken at the scheduled time. Or, as directed by the registered physicians.
পার্শ্বপ্রতিক্রিয়া
Common side effects are Neurotoxicity, Hepatotoxicity.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Neurotoxicity: Among the 176 patients who received Vixo, neurologic adverse reactions of any grade occurred in 53% of patients, including Grade 3 and Grade 4 neurologic adverse reactions in 6% and 0.6% of patients, respectively. The majority (65%) of neurologic adverse reactions occurred within the first three months of treatment (range: 1 day to 2.2 years). Grade 3 neurologic adverse reactions included delirium (2%), dysarthria (1%), dizziness (1%), gait disturbance (1%), and paresthesia (1%). Grade 4 encephalopathy (0.6%) occurred in a single patient. Neurologic adverse reactions leading to dose modification included dizziness (3%), gait disturbance (1%), delirium (1%), memory impairment (1%), and tremor (1%). Patients and caretakers should be advised of these risks with Vixo. Patients should be advised not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions. Vixo should be withheld or permanently discontinued based on the severity. If withheld, Vixo dosage should be modified when resumed.Hepatotoxicity: Among the 176 patients who received Vixo, increased transaminases of any grade occurred in 45%, including Grade 3 increased AST or ALT in 6% of patients. One patient (0.6%) experienced Grade 4 increased ALT. The median time to onset of increased AST was 2 months (range: 1 month to 2.6 years). The median time to onset of increased ALT was 2 months (range: 1 month to 1.1 years). Increased AST and ALT leading to dose modifications occurred in 4% and 6% of patients, respectively. Increased AST or ALT led to permanent discontinuation in 2% of patients. Liver tests should be monitored, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Vixo should be withheld or permanently discontinued based on the severity. If withheld, Vixo dosage should be modified when resumed.Embryo-Fetal Toxicity: Based on literature reports in human subjects with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action, Vixo can cause fetal harm when administered to a pregnant woman. Women should be advised of the potential risk to a fetus. Females of reproductive potential should be advised to use an effective method of contraception during treatment and for 1 week after the final dose of Vixo.
নিষেধাজ্ঞা
It is contraindicated in patients with known hypersensitivity to Larotrectinib or any other components of this product.